Lanean...
A robust prognostic gene expression signature for early stage lung adenocarcinoma
BACKGROUND: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early addition...
Gorde:
| Argitaratua izan da: | Biomark Res |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4761211/ https://ncbi.nlm.nih.gov/pubmed/26900477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-016-0058-3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|